Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 9 million as at August 31, 2023. 5000 +0. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Website. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. VANCOUVER, British Columbia, Nov. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. 51 to 200 Employees. 46. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes of the Company’s. " The 12-month stock price forecast is $18. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies is pepped up on peptides. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. $44. Theratechnologies Inc. com uses cookies on this site. If you have HIV, it's important to know the difference. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. MONTREAL, Sept. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Follow. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. 86 million for the quarter. . sBLA for F8 formulation of tesamorelin submitted to FDA. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Theratechnologies. Theratechnologies Inc. About TH1902. T. com uses cookies on this site. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. Their average twelve-month price target is $36. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. 54% and a negative trailing twelve-month return on equity of 1,116. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. MONTREAL, Jan. Katana shareholders will. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. : Renegotiated Lease to Generate Substantial Annual Savings. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. com uses cookies on this site. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. We currently market. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). T. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. Stockhouse. We also use them to share usage information with our partners. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. 05M. OTCQX – this is the premium tier of OTC stocks. T. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Stockhouse. MONTREAL, Feb. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 26 +15. 08). MONTREAL, Oct. 67, which is an increase of 1,144. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. Volume has increased on the last day along with the price, which is a. Cookies are used to offer you a better browsing experience and to analyze our traffic. Further. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. 22M. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). The company had revenue of $20. We also use them to share usage information with our partners. 89 52. $109. Theratechnologies Inc. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. 16%. By continuing to use our service, you agree to our use of cookies. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. Read More. com uses cookies on this site. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Cookies are used to offer you a better browsing experience and to analyze our traffic. FDA for its IV push form of administration of Trogarzo. ET. These pharmaceuticals. C. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. $30. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies to Announce Financial Results for Its First Quarter 2022. We also use them to share usage information with our partners. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. FY2023 revenue guidance range set between $90 million and $95 million. (TH. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Learn why it. L. Stockhouse. S. View real-time stock prices and stock quotes for a full financial overview. MONTREAL, Nov. THTX earnings call for the period ending February 29, 2020. T. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Stockhouse. com uses cookies on this site. In the United States, Trogarzo ® (ibalizumab. US Headquarters. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. By continuing to use our service, you agree to our use of cookies. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. VANCOUVER, British Columbia, Nov. Stockhouse. S. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. TH | July 20, 2023. Theratechnologies Inc. 28 $1. 8. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 17. By continuing to use our service, you agree to our use of cookies. TO) on CEO. 65 per cent to C$1. MONTREAL, Sept. TH | September 5, 2023. Non-Profit & Charitable Organizations · United States · <25 Employees. com uses cookies on this site. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. RESSOURCES. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. . MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. T. TORONTO, Sept. By continuing to use our service, you agree to our use of cookies. However, only about 4% of the stocks on the OTC market fall into this category. This news release constitutes a “designated news release” for the purposes. 60%. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Real-time discussion about Theratechnologies Inc. 23) earnings per share over the last year ( ($1. Stockhouse. 81 million for the quarter. (TH. Cookies are used to offer you a better browsing experience and to analyze our traffic. By Nick Paul Taylor Jul 12, 2023 8:57am. com uses cookies on this site. TH1902 combines Theratechnologies’ proprietary peptide to. By continuing to use our service, you agree to our use of cookies. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 24 million, 48. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. com uses cookies on this site. - Q3 2022 Consolidated. Cookies are used to offer you a better browsing experience and to analyze our traffic. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. It is the Company’s proprietary. THERATECHNOLOGIES INC. About Us | Theratechnologies Inc. com uses cookies on this site. Conjugating the short peptide with various anti-cancer agents allows for. We also use them to share. com. 49%) At close: 04:00PM EST 1. We also use them to share usage information with our partners. We also use them to share usage. Montréal, Québec, Canada . Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Microsoft to invest $500M in Quebec AI economy. 00%. 71. Image source: The Motley Fool. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. (882) posted 3 minutes ago. Stockhouse. Stockhouse. 66% compared to the previous year's 69. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. com uses cookies on this site. com. . 3. FY2022 revenue. T. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. MONTREAL, Nov. Stockhouse. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. com. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. TH | March 7, 2023. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. com uses cookies on this site. 72%. Stockhouse. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. com uses cookies on this site. GUD | Complete Knight Therapeutics Inc. When this page refreshes you will be logged in with the new address. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. - October 10, 2023) - KO Gold Inc. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. The webinar will also address system-level barriers and present real-world. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. was a. 521. Theratechnologies had a negative net margin of 36. 00 in the next twelve months. Shares of Theratechnologies are up 4. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. US Headquarters. Senior Director, Investor Relations. com 10/16/2023. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. MONTREAL, Aug. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. Theratechnologies Inc. 4 million. 81 million for the quarter. Theratechnologies reduces R&D head count to compensate for sales setback. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. MONTREAL, Jan. Theratechnologies Inc. Theratechnologies Inc. Further. The company was. We currently market prescription products for people with HIV in the United States. MONTREAL, Oct. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. Theratechnologies Appoints New Board Member. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Theratechnologies. com uses cookies on this site. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. MONTREAL, Jan. P. (THTX) NasdaqCM - NasdaqCM Real Time Price. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. Cookies are used to offer you a better browsing experience and to analyze our traffic. 75%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Thank you. NEW YORK, Dec. By continuing to use our service, you agree to our use of cookies. Find the latest Theratechnologies Inc. ET. The company reported ($0. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Cookies are used to offer you a better browsing experience and to analyze our traffic. The business had revenue of $27. Stockhouse. Losses were -47. 2. (Image via Theralase Technologies Inc. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. (TH. home message. is a speaker and consultant of Theratechnologies. 06 million, an increase of 14. 617-356-1009. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. On average, they expect the company's stock price to reach $36. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. Stockhouse. 35 as of 10:41 a. By continuing to use our service, you agree to our use of cookies. MONTREAL, Dec. 4%. Stockhouse. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. Theratechnologies Announces 1-for-4 Reverse Stock Split. Agreement in principle on key amendments to loan. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. Stockhouse. 9 million as at August 31, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. Who is Theratechnologies. MONTREAL, Oct. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. 65 per cent to C$1. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. $103. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. 51 S1. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). . 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 20% from a day low at $1. com uses cookies on this site. Theratechnologies Inc. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Investor Relations. 74M. By continuing to use our service, you agree to our use of cookies. Theratechnologies had a negative net margin of 36. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. com uses cookies on this site. 63. Visit the TSX ETF Investor Centre to access our screener and comparison tool. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Company Description: Theratechnologies is pepped up on peptides. 08 (+6. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Senior Director, Investor Relations. This news release constitutes a "designated news release" for the purposes of. 617-356-1009. During the last trading day the stock fluctuated 4.